【摘要】 目的探讨氯沙坦钾对原发性高血压患者高敏C反应蛋白(hs-CRP)及稳态模型评估的胰岛素抵抗指数(HOMA-IR)的影响。方法选择51例轻中度原发性高血压患者,经2周安慰剂洗脱后随机分为2组,治疗组给予氯沙坦钾,每日50mg,对照组给予硝苯地平缓释片10mg,每日2次。疗程为8周。在2周洗脱期末及8周末空腹抽静脉血,测定hs–CRP、血糖、胰岛素水平,用HOMA-IR公式计算胰岛素抵抗指数。比较治疗前后hs–CRP、空腹胰岛素、HOMA–IR变化。结果两组患者治疗8周后,收缩压、舒张压均有显著下降,差异有统计学意义(P<0.001);氯沙坦组治疗后血清hs-CRP、空腹胰岛素水平、HOMA-IR明显降低,与治疗前比较差异有统计学意义(P<0.05)。对照组治疗后hs-CRP、空腹胰岛素水平、HOMA-IR与治疗前比较差异无统计学意义(P>0.05)。氯沙坦组治疗前后hs-CRP、空腹胰岛素水平、HOMA-IR变化值与对照组比较差异有统计学意义(P<0.05,P<0.01,P<0.05)。两组治疗前后血糖水平差异无统计学意义。结论氯沙坦钾有效控制血压,降低hs-CRP水平,有改善胰岛素抵抗作用。更多还原

【Abstract】 Objective To investigate the effect of losartan on serum high-sensitivity C-reactive protein (hs-CRP)and insulin resistance in hypertensive patients. Methods After two weeks of single blind placebo period ,51 hypertensive patients were divided into experimental group (losartan 50 mg , once per day) and control group(nifidipine 10mg twice per day)for eight weeks for both groups. The level of fasting blood glucose ( FBG) , fasting insulin ( FINS) , HOMA-IR and hs-CRP were evaluated before and the end of treatment. Results SBP and DBP were significantly reduced in two groups after treatment ( P < 0. 001) .The level of hs-CRP ,FINS and HOMA-IR were significantly decreased in experimental group after treatment(P <0.05, P <0.01,P <0.05, respectively).There was no significant differences in FBG in both groups . Conclusion Losartan can reduce hs-CRP and improve insulin resistance in hypertensive patients.更多还原